COVID-19
Conditions
Keywords
children, pediatric department
Brief summary
In early December 2019, cases of pneumonia of unknown origin were reported in Wuhan, Hubei Province in the People's Republic of China. The disease spreads rapidly and the number of sick people is increasing. On January 3, 2020 a new virus of the coronavirus family is identified in samples of bronchoalveolar lavage fluid from a patient in Wuhan and subsequently confirmed as the cause of these pneumonias. On 7 January 2020, the World Health Organization (WHO) designated it as the new coronavirus 2019 (i.e. 2019-nCoV). On 11 February 2020, the WHO designated the disease associated with 2019-nCoV as coronavirus 2019 disease (COVID-19). On 12 March, WHO announced that the COVID-19 outbreak is a pandemic. As of March 24, 2020, more than 375,000 cases of COVID-19 had been diagnosed with more than 16,000 deaths attributed to this virus. (Ref WHO https://www.who.int/emergencies/diseases/novel-coronavirus-2019 ). In France, the number of cases rose from 105 cases at the end of February to 19615 confirmed cases on March 24. (Source Public Health France). Most of the cases are adults. However, children are not completely spared and serious cases have been described. These severe cases can be respiratory or extra-respiratory (e.g. myocarditis). We also know that pediatric and adult cases differ in terms of clinical, biological and imaging findings, particularly chest CT scans. However, the description of paediatric pictures, especially severe forms and the involvement of children suffering from co-morbidities, remains poorly reported. Finally, the risk factors for serious cases in children remain largely unknown. This observatory aim to describe the clinical phenotypes of hospitalized pediatric patients with Covid19 in France, according to age groups. Moreover for a subgroup of patients, informations regarding the long covid will be reported.
Interventions
OTHERhospitalized children with Covid19
All patients under 18 years hospitalized with a covid19 diagnosis
Sponsors
Association Clinique Thérapeutique Infantile du val de Marne
Groupe de Pathologies Infectieuses Pédiatriques (GPIP)
Société Française de Pédiatrie
Francophone Pediatric Resuscitation and Emergency Group (GFRUP)
Centre Hospitalier Intercommunal Creteil
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children \< 18 years old * Admitted in French pediatric wards * With a confirmed COVID-19 infection. ( on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs
Exclusion criteria
* Expressed refusal to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of children with severe or critical form. | Day 14 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical symptoms of children | at admission | requiring intensive care support or not |
| Biological results of children | at admission | requiring intensive care support or not |
| CT chest of children | at admission | requiring intensive care support or not |
| Pulmonary echography | Day 14 | requiring intensive care support or not |
| Percentage of children requiring intensive care support | at admission | — |
| nasopharynx sarscov2 load | at day 7 | if available |
| nasopharynx multiplex PCR | at admission | if available |
| number of hospital days | up to 12months | days |
| Evaluation of long covid | up to 12months | — |
| nasopharynx SARScov2 PCR | at admission | — |
Countries
France
Contacts
Primary ContactCorinne Levy, MD
Outcome results
None listed